{"pmid":32442105,"title":"The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells.","text":["The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells.","SARS-COV-2 has recently emerged as a new public health threat. Herein, we report that the FDA-approved drug, auranofin, inhibits SARS-COV-2 replication in human cells at low micro molar concentration. Treatment of cells with auranofin resulted in a 95% reduction in the viral RNA at 48 h after infection. Auranofin treatment dramatically reduced the expression of SARS-COV-2-induced cytokines in human cells. These data indicate that auranofin could be a useful drug to limit SARS-CoV-2 infection and associated lung injury due to its antiviral, anti-inflammatory and anti-reactive oxygen species (ROS) properties. Further animal studies are warranted to evaluate the safety and efficacy of auranofin for the management of SARS-COV-2 associated disease.","Virology","Rothan, Hussin A","Stone, Shannon","Natekar, Janhavi","Kumari, Pratima","Arora, Komal","Kumar, Mukesh","32442105"],"abstract":["SARS-COV-2 has recently emerged as a new public health threat. Herein, we report that the FDA-approved drug, auranofin, inhibits SARS-COV-2 replication in human cells at low micro molar concentration. Treatment of cells with auranofin resulted in a 95% reduction in the viral RNA at 48 h after infection. Auranofin treatment dramatically reduced the expression of SARS-COV-2-induced cytokines in human cells. These data indicate that auranofin could be a useful drug to limit SARS-CoV-2 infection and associated lung injury due to its antiviral, anti-inflammatory and anti-reactive oxygen species (ROS) properties. Further animal studies are warranted to evaluate the safety and efficacy of auranofin for the management of SARS-COV-2 associated disease."],"journal":"Virology","authors":["Rothan, Hussin A","Stone, Shannon","Natekar, Janhavi","Kumari, Pratima","Arora, Komal","Kumar, Mukesh"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32442105","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.virol.2020.05.002","keywords":["anti-inflammatory","antiviral","auranofin","covid-19","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667523504765927425,"score":9.490897,"similar":[{"pmid":32251768,"pmcid":"PMC7129059","title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.","text":["The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.","Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.","Antiviral Res","Caly, Leon","Druce, Julian D","Catton, Mike G","Jans, David A","Wagstaff, Kylie M","32251768"],"abstract":["Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans."],"journal":"Antiviral Res","authors":["Caly, Leon","Druce, Julian D","Catton, Mike G","Jans, David A","Wagstaff, Kylie M"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32251768","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.antiviral.2020.104787","topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138490965852160,"score":283.62164},{"pmid":32360580,"pmcid":"PMC7192119","title":"Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-kappaB signaling pathway.","text":["Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-kappaB signaling pathway.","Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread worldwide through person-to-person contact, causing a public health emergency of international concern. At present, there is no specific antiviral treatment recommended for SARS-CoV-2 infection. Liu Shen capsule (LS), a traditional Chinese medicine, has been proven to have a wide spectrum of pharmacological properties, such as anti-inflammatory, antiviral and immunomodulatory activities. However, little is known about the antiviral effect of LS against SARS-CoV-2. Herein, the study was designed to investigate the antiviral activity of SARS-CoV-2 and its potential effect in regulating the host's immune response. The inhibitory effect of LS against SARS-CoV-2 replication in Vero E6 cells was evaluated by using the cytopathic effect (CPE) and plaque reduction assay. The number of virions of SARS-CoV-2 was observed under transmission electron microscope after treatment with LS. Proinflammatory cytokine expression levels upon SARS-CoV-2 infection in Huh-7 cells were measured by real-time quantitative PCR assays. The results showed that LS could significantly inhibit SARS-CoV-2 replication in Vero E6 cells, and reduce the number of virus particles and it could markedly reduce pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta, IL-8, CCL-2/MCP-1 and CXCL-10/IP-10) production at the mRNA levels. Moreover, the expression of the key proteins in the NF-kappaB/MAPK signaling pathway was detected by western blot and it was found that LS could inhibit the expression of p-NF-kappaB p65, p-IkappaBalpha and p-p38 MAPK, while increasing the expression of IkappaBalpha. These findings indicate that LS could inhibit SARS-CoV-2 virus infection via downregulating the expression of inflammatory cytokines induced virus and regulating the activity of NF-kappaB/MAPK signaling pathway in vitro, making its promising candidate treatment for controlling COVID-19 disease.","Pharmacol Res","Ma, Qinhai","Pan, Weiqi","Li, Runfeng","Liu, Bin","Li, Chufang","Xie, Yuqi","Wang, Zhoulang","Zhao, Jin","Jiang, Haiming","Huang, Jicheng","Shi, Yongxia","Dai, Jun","Zheng, Kui","Li, Xiaobo","Yang, Zifeng","32360580"],"abstract":["Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread worldwide through person-to-person contact, causing a public health emergency of international concern. At present, there is no specific antiviral treatment recommended for SARS-CoV-2 infection. Liu Shen capsule (LS), a traditional Chinese medicine, has been proven to have a wide spectrum of pharmacological properties, such as anti-inflammatory, antiviral and immunomodulatory activities. However, little is known about the antiviral effect of LS against SARS-CoV-2. Herein, the study was designed to investigate the antiviral activity of SARS-CoV-2 and its potential effect in regulating the host's immune response. The inhibitory effect of LS against SARS-CoV-2 replication in Vero E6 cells was evaluated by using the cytopathic effect (CPE) and plaque reduction assay. The number of virions of SARS-CoV-2 was observed under transmission electron microscope after treatment with LS. Proinflammatory cytokine expression levels upon SARS-CoV-2 infection in Huh-7 cells were measured by real-time quantitative PCR assays. The results showed that LS could significantly inhibit SARS-CoV-2 replication in Vero E6 cells, and reduce the number of virus particles and it could markedly reduce pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta, IL-8, CCL-2/MCP-1 and CXCL-10/IP-10) production at the mRNA levels. Moreover, the expression of the key proteins in the NF-kappaB/MAPK signaling pathway was detected by western blot and it was found that LS could inhibit the expression of p-NF-kappaB p65, p-IkappaBalpha and p-p38 MAPK, while increasing the expression of IkappaBalpha. These findings indicate that LS could inhibit SARS-CoV-2 virus infection via downregulating the expression of inflammatory cytokines induced virus and regulating the activity of NF-kappaB/MAPK signaling pathway in vitro, making its promising candidate treatment for controlling COVID-19 disease."],"journal":"Pharmacol Res","authors":["Ma, Qinhai","Pan, Weiqi","Li, Runfeng","Liu, Bin","Li, Chufang","Xie, Yuqi","Wang, Zhoulang","Zhao, Jin","Jiang, Haiming","Huang, Jicheng","Shi, Yongxia","Dai, Jun","Zheng, Kui","Li, Xiaobo","Yang, Zifeng"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32360580","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.phrs.2020.104850","keywords":["liu shen capsule","sars-cov-2","anti-inflammatory","antiviral"],"locations":["Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495914082304,"score":245.42476},{"pmid":32364011,"title":"FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication.","text":["FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication.","Emergent novel SARS-CoV-2 is responsible for the current pandemic outbreak of severe acute respiratory syndrome with high mortality among the symptomatic population worldwide. Given the absence of a current vaccine or specific antiviral treatment, it is urgent to search for FDA-approved drugs that can potentially inhibit essential viral enzymes. The inhibition of 3CL(pro) has potential medical application, due to the fact that it is required for processing of the first translated replicase polyproteins into a series of native proteins, which are essential for viral replication in the host cell. We employed an in silico approach to test if disulfiram, as well as its metabolites, and captopril could be used as potential antiviral drugs against COVID-19. We provide data on the potential covalent interaction of disulfiram and its metabolites with the substrate binding subsite of 3CL(pro) and propose a possible mechanism for the irreversible protease inactivation thought the reaction of the aforementioned compounds with the Cys145. Although, captopril is shown to be a potential ligand of 3CL(pro), it is not recommended anti-COVID-19 therapy, due to the fact that it can induce the expression of the viral cellular receptor such as, angiotensin-converting enzyme ACE-2, and thus, making the patient potentially more susceptible to infection. On the other hand, disulfiram, an alcoholism-averting drug, has been previously proposed as an antimicrobial and anti-SARS and MERS agent, safe to use even at higher doses with low side effects, it is recommended to be tested for control of SARS-CoV-2 infection.","J Biomol Struct Dyn","Lobo-Galo, Naun","Terrazas-Lopez, Manuel","Martinez-Martinez, Alejandro","Diaz-Sanchez, Angel Gabriel","32364011"],"abstract":["Emergent novel SARS-CoV-2 is responsible for the current pandemic outbreak of severe acute respiratory syndrome with high mortality among the symptomatic population worldwide. Given the absence of a current vaccine or specific antiviral treatment, it is urgent to search for FDA-approved drugs that can potentially inhibit essential viral enzymes. The inhibition of 3CL(pro) has potential medical application, due to the fact that it is required for processing of the first translated replicase polyproteins into a series of native proteins, which are essential for viral replication in the host cell. We employed an in silico approach to test if disulfiram, as well as its metabolites, and captopril could be used as potential antiviral drugs against COVID-19. We provide data on the potential covalent interaction of disulfiram and its metabolites with the substrate binding subsite of 3CL(pro) and propose a possible mechanism for the irreversible protease inactivation thought the reaction of the aforementioned compounds with the Cys145. Although, captopril is shown to be a potential ligand of 3CL(pro), it is not recommended anti-COVID-19 therapy, due to the fact that it can induce the expression of the viral cellular receptor such as, angiotensin-converting enzyme ACE-2, and thus, making the patient potentially more susceptible to infection. On the other hand, disulfiram, an alcoholism-averting drug, has been previously proposed as an antimicrobial and anti-SARS and MERS agent, safe to use even at higher doses with low side effects, it is recommended to be tested for control of SARS-CoV-2 infection."],"journal":"J Biomol Struct Dyn","authors":["Lobo-Galo, Naun","Terrazas-Lopez, Manuel","Martinez-Martinez, Alejandro","Diaz-Sanchez, Angel Gabriel"],"date":"2020-05-05T11:00:00Z","year":2020,"_id":"32364011","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1080/07391102.2020.1764393","keywords":["3cl main protease","covid-19","sars-cov-2","disulfiram","thiol-reacting drugs"],"locations":["thiol"],"e_drugs":["Captopril","Disulfiram","Sulfhydryl Compounds"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496018939908,"score":222.05292},{"pmid":32374474,"title":"Natural antiviral compound silvestrol modulates human monocyte-derived macrophages and dendritic cells.","text":["Natural antiviral compound silvestrol modulates human monocyte-derived macrophages and dendritic cells.","Outbreaks of infections with viruses like Sars-CoV-2, Ebola virus and Zika virus lead to major global health and economic problems because of limited treatment options. Therefore, new antiviral drug candidates are urgently needed. The promising new antiviral drug candidate silvestrol effectively inhibited replication of Corona-, Ebola-, Zika-, Picorna-, Hepatis E and Chikungunya viruses. Besides a direct impact on pathogens, modulation of the host immune system provides an additional facet to antiviral drug development because suitable immune modulation can boost innate defence mechanisms against the pathogens. In the present study, silvestrol down-regulated several pro- and anti-inflammatory cytokines (IL-6, IL-8, IL-10, CCL2, CCL18) and increased TNF-alpha during differentiation and activation of M1-macrophages, suggesting that the effects of silvestrol might cancel each other out. However, silvestrol amplified the anti-inflammatory potential of M2-macrophages by increasing expression of anti-inflammatory surface markers CD206, TREM2 and reducing release of pro-inflammatory IL-8 and CCL2. The differentiation of dendritic cells in the presence of silvestrol is characterized by down-regulation of several surface markers and cytokines indicating that differentiation is impaired by silvestrol. In conclusion, silvestrol influences the inflammatory status of immune cells depending on the cell type and activation status.","J Cell Mol Med","Blum, Leonard","Geisslinger, Gerd","Parnham, Michael J","Grunweller, Arnold","Schiffmann, Susanne","32374474"],"abstract":["Outbreaks of infections with viruses like Sars-CoV-2, Ebola virus and Zika virus lead to major global health and economic problems because of limited treatment options. Therefore, new antiviral drug candidates are urgently needed. The promising new antiviral drug candidate silvestrol effectively inhibited replication of Corona-, Ebola-, Zika-, Picorna-, Hepatis E and Chikungunya viruses. Besides a direct impact on pathogens, modulation of the host immune system provides an additional facet to antiviral drug development because suitable immune modulation can boost innate defence mechanisms against the pathogens. In the present study, silvestrol down-regulated several pro- and anti-inflammatory cytokines (IL-6, IL-8, IL-10, CCL2, CCL18) and increased TNF-alpha during differentiation and activation of M1-macrophages, suggesting that the effects of silvestrol might cancel each other out. However, silvestrol amplified the anti-inflammatory potential of M2-macrophages by increasing expression of anti-inflammatory surface markers CD206, TREM2 and reducing release of pro-inflammatory IL-8 and CCL2. The differentiation of dendritic cells in the presence of silvestrol is characterized by down-regulation of several surface markers and cytokines indicating that differentiation is impaired by silvestrol. In conclusion, silvestrol influences the inflammatory status of immune cells depending on the cell type and activation status."],"journal":"J Cell Mol Med","authors":["Blum, Leonard","Geisslinger, Gerd","Parnham, Michael J","Grunweller, Arnold","Schiffmann, Susanne"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32374474","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/jcmm.15360","keywords":["rna viruses","antiviral","cytokines","eif4a","energy metabolism","immune modulation","rocaglate"],"locations":["Chikungunya"],"e_drugs":["silvestrol"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138496514916352,"score":211.81949},{"pmid":32473310,"title":"Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.","text":["Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.","Coronavirus Disease 2019 (COVID-19) caused by the emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with a crude case fatality rate of about 0.5-10% depending on locality. A few clinically approved drugs, such as remdesivir, chloroquine, hydroxychloroquine, nafamostat, camostat, and ivermectin, exhibited anti-SARS-CoV-2 activity in vitro and/or in a small number of patients. However, their clinical use may be limited by anti-SARS-CoV-2 50% maximal effective concentrations (EC50) that exceeded their achievable peak serum concentrations (Cmax), side effects, and/or availability. To find more immediately available COVID-19 antivirals, we established a two-tier drug screening system that combines SARS-CoV-2 enzyme-linked immunosorbent assay and cell viability assay, and applied it to screen a library consisting 1528 FDA-approved drugs. Cetilistat (anti-pancreatic lipase), diiodohydroxyquinoline (anti-parasitic), abiraterone acetate (synthetic androstane steroid), and bexarotene (antineoplastic retinoid) exhibited potent in vitro anti-SARS-CoV-2 activity (EC50 1.13-2.01microM). Bexarotene demonstrated the highest Cmax:EC50 ratio (1.69) which was higher than those of chloroquine, hydroxychloroquine, and ivermectin. These results demonstrated the efficacy of the two-tier screening system and identified potential COVID-19 treatments which can achieve effective levels if given by inhalation or systemically depending on their pharmacokinetics.","Pharmacol Res","Yuan, Shuofeng","Chan, Jasper F W","Chik, Kenn K H","Chan, Chris C Y","Tsang, Jessica O L","Liang, Ronghui","Cao, Jianli","Tang, Kaiming","Chen, Lin-Lei","Wen, Kun","Cai, Jian-Piao","Ye, Zi-Wei","Lu, Gang","Chu, Hin","Jin, Dong-Yan","Yuen, Kwok-Yung","32473310"],"abstract":["Coronavirus Disease 2019 (COVID-19) caused by the emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is associated with a crude case fatality rate of about 0.5-10% depending on locality. A few clinically approved drugs, such as remdesivir, chloroquine, hydroxychloroquine, nafamostat, camostat, and ivermectin, exhibited anti-SARS-CoV-2 activity in vitro and/or in a small number of patients. However, their clinical use may be limited by anti-SARS-CoV-2 50% maximal effective concentrations (EC50) that exceeded their achievable peak serum concentrations (Cmax), side effects, and/or availability. To find more immediately available COVID-19 antivirals, we established a two-tier drug screening system that combines SARS-CoV-2 enzyme-linked immunosorbent assay and cell viability assay, and applied it to screen a library consisting 1528 FDA-approved drugs. Cetilistat (anti-pancreatic lipase), diiodohydroxyquinoline (anti-parasitic), abiraterone acetate (synthetic androstane steroid), and bexarotene (antineoplastic retinoid) exhibited potent in vitro anti-SARS-CoV-2 activity (EC50 1.13-2.01microM). Bexarotene demonstrated the highest Cmax:EC50 ratio (1.69) which was higher than those of chloroquine, hydroxychloroquine, and ivermectin. These results demonstrated the efficacy of the two-tier screening system and identified potential COVID-19 treatments which can achieve effective levels if given by inhalation or systemically depending on their pharmacokinetics."],"journal":"Pharmacol Res","authors":["Yuan, Shuofeng","Chan, Jasper F W","Chik, Kenn K H","Chan, Chris C Y","Tsang, Jessica O L","Liang, Ronghui","Cao, Jianli","Tang, Kaiming","Chen, Lin-Lei","Wen, Kun","Cai, Jian-Piao","Ye, Zi-Wei","Lu, Gang","Chu, Hin","Jin, Dong-Yan","Yuen, Kwok-Yung"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32473310","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.phrs.2020.104960","keywords":["abiraterone acetate (pubchem cid: 9821849)","bexarotene (pubchem cid: 82146)","covid-19","cetilistat (pubchem cid: 9952916)","diiodohydroxyquinoline (pubchem cid: 3728)","sars-cov-2","abiraterone","antiviral","bexarotene","cetilistat","coronavirus","diiodohydroxyquinoline","library","treatment"],"topics":["Treatment"],"weight":1,"_version_":1668255193390645250,"score":194.73924}]}